查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2012592

癌症診斷市場：按技術、癌症類型和最終用戶分類－2026年至2032年全球市場預測

Cancer Diagnostics Market by Technology, Cancer Type, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025年癌症診斷市值為370.2億美元，預計到2026年將成長至411.5億美元，複合年成長率為12.26%，到2032年將達到832.3億美元。

主要市場統計數據
基準年 2025 370.2億美元
預計年份：2026年 411.5億美元
預測年份 2032 832.3億美元
複合年成長率 (%) 12.26%

對受技術融合、治療過程變革和監管變化驅動的腫瘤診斷格局的緊迫而全面的展望。

腫瘤診斷領域正經歷快速發展，主要得益於技術融合、監管改革和臨床路徑的轉變。分子診斷平台、高解析度成像和先進細胞分析技術的進步，大大提升了臨床醫生和研究人員檢測、分型和監測癌症的能力，其精準度達到了前所未有的水平。同時，隨著診斷決策越來越貼近患者，醫療服務模式也在發生變化，多學科團隊需要整合來自組織病理學、基因組定序和影像衍生生物標記的資訊。

技術民主化、多模態資料整合和監管重組如何共同重新定義腫瘤學的診斷路徑和商業性需求。

腫瘤診斷格局正經歷一系列相互關聯的變革，這些變革共同重塑臨床實踐和商業性機會。科技的普及化是其中的核心主題。檢測流程的簡化和自動化，以及透過數位化介面實現結果解讀的標準化，正將曾經局限於專業實驗室的平台推廣至常規醫院檢查室和門診機構。這種普及加速了分子診斷和先進免疫檢測在社區醫療機構的應用，從而實現更早期的疾病檢測和更精細的疾病分層。

評估 2025 年美國關稅措施對供應鏈、採購成本和診斷技術策略部署的多方面影響。

美國2025年宣布或實施的關稅調整將對腫瘤診斷領域的企業產生複雜的上下游影響。最直接的影響是，進口設備和試劑關稅的提高可能會推高成像設備、流式細胞儀和定序儀等昂貴設備以及國內尚無成熟替代產品的專用耗材的最終採購成本。這些成本壓力可能會擠壓依賴全球供應鏈的製造商的利潤空間，並增加進口設備或依賴外國試劑的檢查室和醫療系統的部署成本和單次檢測成本。

基於細分的詳細洞察，繪製特定技術的價值鏈、特定癌症的診斷需求以及多樣化的最終用戶採用路徑，從而實現策略優先排序。

精細化的細分觀點揭示了每種技術平台、癌症類型和終端用戶管道的不同機會和風險特徵，從而為產品定位和商業化提供了清晰的策略方向。在技​​術領域，流式細胞技術分為細胞分選和多參數流式細胞技術兩大類，各自擁有獨特的臨床和研究應用。細胞分選對於轉化研究和自體細胞治療仍然至關重要，而多參數流式細胞技術則在血液學診斷中推進免疫表現型分析和微量殘存疾病評估。影像技術包括電腦斷層掃描（CT）、磁振造影（MRI）、超音波，每種方式在診斷、分期和治療監測方面都具有獨特的價值。 PET 和 MRI 尤其重要，因為其代謝和功能性觀察有助於標靶治療的選擇，而 CT 和超音波繼續在急診和門診環境中提供廣泛的應用和快速影像。

世界各地不同的報銷制度、法規結構和醫療保健基礎設施如何影響實施重點和商業策略？

區域趨勢對美洲、歐洲、中東和非洲以及亞太地區的技術採納、報銷途徑和夥伴關係模式有顯著影響，每個地區都擁有其獨特的醫療保健結構和創新生態系統。在美洲，成熟的私營和公共保險公司與領先的學術研究中心和強大的商業診斷產業並存。這種環境有利於高價值分子檢測和先進影像技術的快速應用，同時也需要強力的證據支持項目來確保報銷和處方藥資格。此外，美洲的採購慣例傾向於簽訂綜合性長期服務契約，這對於能夠提供全面售後服務和耗材供應網路的供應商而言具有優勢。

平台的規模、測試方法的專業性、服務的經濟性以及策略聯盟塑造的競爭動態——所有這些因素共同決定了商業性韌性和成長軌跡。

腫瘤診斷領域的競爭動態由大規模綜合平台供應商、專業檢測方法開發公司以及專注於特定臨床應用的敏捷型新興參與企業共同構成。成熟的儀器製造商利用其規模、廣泛的服務網路和整合的耗材生態系統來維護現有基本客群，而專業公司則透過檢測方法創新、軟體驅動的分析以及與臨床中心的策略合作來脫穎而出。在整個競爭格局中，差異化越來越依賴於展現臨床效用、透過自動化簡化檢查室工作流程以及提供永續的服務和試劑供應鏈的能力。

領導企業為增強供應鏈韌性、證據產生和整合臨床部署以實現永續成長而採取的優先策略行動。

產業領導企業應採取切實可行且優先排序的措施，將新興趨勢轉化為永續的競爭優勢。首先，投資於供應鏈透明度和多元化，以減輕關稅和貿易中斷的影響。這包括探索替代供應商、評估區域合作生產和共同生產的機會，以及實施平衡營運資本和供應連續性的庫存策略。其次，制定藍圖，以產生能夠證明關鍵適應症的臨床效用和健康經濟價值的證據。儘早投資於前瞻性研究和真實世界數據將加快支付方的參與，並促進報銷談判，尤其是在高成本分子檢測和伴隨診斷方面。

一個穩健的混合方法研究框架，結合了相關人員訪談、文獻整合、定量映射和專家檢驗，以確保基於證據的見解。

本次高階主管綜合研究採用混合方法，旨在整合來自多個互補資訊來源的見解，並透過專家諮詢檢驗這些見解。主要研究包括對醫院、診斷檢查室和研究機構的臨床負責人、實驗室主任和採購主管進行結構化訪談，並輔以對診斷設備製造商和技術供應商的高級管理人員的訪談。這些工作提供了有關應用促進因素、採購限制以及影響報銷決策的證據需求的定性背景資訊。

策略性問題整合：臨床效用、供應鏈韌性和綜合解決方案決定了腫瘤診斷的長期成功。

綜合以上分析表明，腫瘤診斷生態系統正處於策略轉折點，技術可能性、支付方期望和供應鏈現實在此交匯。對於那些能夠將技術差異化轉化為可證實的臨床價值，同時在貿易和採購環境波動的情況下維持營運韌性的機構而言，存在著許多機會。多模態診斷和整合報告的發展趨勢將越來越有利於那些提供互通解決方案並積極與臨床相關人員合作，將診斷整合到診療路徑中的供應商。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：癌症診斷市場：依技術分類

  • 流式細胞技術
    • 細胞分選
    • 多參數流式細胞技術
  • 影像
    • 電腦斷層掃描
    • 磁振造影
    • 正子斷層掃描
    • 超音波
  • 免疫組織化學
    • 顯色方法
    • 螢光
  • 原位雜合反應
  • 分子診斷
    • 微陣列
    • PCR
    • 定序

第9章：以癌症類型分類的癌症診斷市場

  • 血癌
    • 白血病
    • 淋巴瘤
    • 多發性骨髓瘤
  • 固體癌
    • 乳癌
    • 結腸癌
    • 肺癌
    • 攝護腺癌

第10章 癌症診斷市場：依最終用戶分類

  • 門診治療
  • 診斷檢查室
  • 醫院
  • 研究機構
    • 學術機構
    • 私人研究機構

第11章 癌症診斷市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第12章 癌症診斷市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第13章 癌症診斷市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第14章：美國癌症診斷市場

第15章：中國癌症診斷市場

第16章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • Agilent Technologies, Inc.
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • bioMerieux SA
  • Canon Medical Systems Corporation
  • Danaher Corporation
  • Danaher Corporation
  • DiaSorin SpA
  • F. Hoffmann-La Roche Ltd
  • Fujifilm Corporation
  • GE HealthCare Technologies Inc.
  • Hologic, Inc.
  • Illumina, Inc.
  • Myriad Genetics, Inc.
  • NeoGenomics Laboratories, Inc.
  • PerkinElmer, Inc.
  • QIAGEN NV
  • Quest Diagnostics Incorporated
  • Siemens Healthineers AG
  • Sysmex Corporation
  • Thermo Fisher Scientific Inc.
Product Code: MRR-436145BF8B0C

The Cancer Diagnostics Market was valued at USD 37.02 billion in 2025 and is projected to grow to USD 41.15 billion in 2026, with a CAGR of 12.26%, reaching USD 83.23 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 37.02 billion
Estimated Year [2026] USD 41.15 billion
Forecast Year [2032] USD 83.23 billion
CAGR (%) 12.26%

An urgent and comprehensive orientation to the evolving oncology diagnostics environment driven by technology convergence, care pathway transformation, and regulatory shifts

The oncology diagnostics landscape is experiencing a period of rapid evolution driven by technological convergence, regulatory recalibration, and shifting clinical pathways. Advances across molecular platforms, high-resolution imaging, and sophisticated cellular analytics are expanding the capabilities of clinicians and researchers to detect, subtype, and monitor cancer with unprecedented precision. At the same time, care delivery models are changing as diagnostic decision-making migrates closer to the patient, and as multidisciplinary teams demand integrated information flows that combine histopathology, genomic sequencing, and imaging-derived biomarkers.

Against this backdrop, market participants face a complex interplay of innovation opportunities and operational challenges. Diagnostic developers are competing on assay sensitivity and specificity, throughput, and cost of ownership, while health systems increasingly emphasize value-based outcomes and diagnostic efficiency. Regulatory expectations for companion diagnostics and next-generation sequencing workflows are maturing, and payers are reassessing reimbursement pathways for tests that promise improved treatment selection and reduced downstream costs. As a result, the competitive environment rewards organizations that can pair scientific rigor with pragmatic deployment strategies that address clinical workflows and reimbursement realities.

This executive summary synthesizes the most consequential trends reshaping cancer diagnostics, analyzes potential policy and tariff-driven disruptions, delineates segmentation-level insights across technology, cancer type, and end user, evaluates regional dynamics, and identifies strategic options for companies seeking to sharpen their competitive positioning. The subsequent sections provide a cohesive narrative designed to inform corporate strategy, investment decisions, and operational planning across stakeholder groups involved in oncology diagnostics and associated services.

How technological democratization, multimodal data integration, and regulatory realignment are jointly redefining diagnostic pathways and commercial imperatives in oncology

The diagnostic oncology landscape is being transformed by a set of interrelated shifts that together are redefining clinical practice and commercial opportunity. Technological democratization is a central theme: platforms once confined to specialized reference laboratories are moving into routine hospital laboratories and ambulatory settings as assay workflows are simplified, automation increases, and digital interfaces standardize results interpretation. This diffusion is accelerating the adoption of molecular diagnostics and advanced immunoassays in community settings, enabling earlier detection and more granular disease stratification.

Simultaneously, the integration of multimodal data streams is reshaping diagnostic outputs. Clinicians now expect reports that combine genomic findings with immunohistochemical patterns, spatial profiling, and cross-sectional imaging biomarkers, creating more actionable diagnostic narratives for precision therapy selection and longitudinal monitoring. This shift incentivizes cross-disciplinary collaboration between pathology, radiology, and molecular diagnostic teams, and it favors companies that can offer interoperable systems or curated data platforms that reduce friction in data synthesis.

Payer and regulatory environments are also influencing strategic direction. Payers are increasingly focused on demonstrable clinical utility and real-world outcomes, prompting diagnostic developers to invest in evidence-generation programs and outcomes studies. Regulators are adapting frameworks to address novel test modalities, companion diagnostics, and decentralized testing, which is accelerating the need for robust analytical validation and post-market surveillance. Finally, supply chain resilience and cost pressures are prompting manufacturing realignment and more selective procurement practices, encouraging vertical integration and strategic alliances focused on securing critical reagent supplies and instrument service networks.

Taken together, these transformative shifts create a landscape where technological innovation alone is insufficient; success requires interoperable solutions, evidence-driven adoption strategies, and operational resilience that collectively enable diagnostics to be both clinically impactful and commercially sustainable.

Assessing the multi-dimensional consequences of 2025 U.S. tariff measures on supply chains, procurement costs, and strategic deployment of diagnostic technologies

Tariff changes announced or implemented in 2025 in the United States present a complex set of upstream and downstream implications for companies operating in the diagnostic oncology space. At the most direct level, increased duties on imported instruments and reagents can raise landed costs for high-capital equipment such as imaging modalities, flow cytometers, and sequencers, as well as for specialized consumables that lack mature domestic manufacturing alternatives. These cost pressures can compress margins for manufacturers that rely on global supply chains and can increase acquisition and per-test costs for laboratories and health systems that import equipment or rely on foreign-produced reagents.

Beyond direct pricing effects, tariffs can precipitate strategic responses across the value chain. Manufacturers may accelerate regionalization of production, shift sourcing to tariff-exempt suppliers, or redesign products to incorporate components that are domestically available. Such adjustments can reduce exposure over time but may require capital investment, requalification of supply chains, and renegotiation of service contracts, each of which can introduce implementation risk and near-term cost volatility. Laboratories and hospitals may respond by modifying procurement cycles, consolidating purchasing, or entering into longer-term service and consumable agreements to stabilize unit costs, which could favor vendors with broad service footprints and flexible commercial terms.

Tariffs also materially affect the economics of decentralized testing adoption. If the incremental cost of portable or point-of-care devices rises due to duties on critical components, deployment decisions may favor centralized high-throughput models where economies of scale can partially neutralize tariff impacts. Conversely, tariffs that disproportionately affect specialized reagents could shift demand toward alternative diagnostic modalities with lower import exposure, potentially accelerating investment in domestically manufactured assays or in technologies that rely more on software and analytics than on high-cost consumables.

In addition, tariff-induced uncertainty has implications for clinical research and development. Sponsors conducting multi-site trials that require imported diagnostic kits may face higher trial costs and longer timelines for kit distribution and regulatory compliance. This could influence site selection and the timing of companion diagnostic rollouts. Finally, the cumulative impact of tariffs should be viewed through a strategic lens: in environments of sustained trade policy volatility, organizations that invest in supply chain transparency, diversified sourcing, and adaptive pricing strategies will be better positioned to maintain service levels and preserve market access in core clinical and commercial channels.

Deep segmentation-driven insights that map technology-specific value chains, cancer-type diagnostic needs, and varied end-user adoption pathways for strategic prioritization

A granular segmentation lens reveals differentiated opportunity and risk profiles across technological platforms, cancer types, and end-user channels, offering strategic clarity for product positioning and commercialization. Within technology, flow cytometry splits into cell sorting and multiparameter flow cytometry segments, each with distinct clinical and research applications; cell sorting remains essential for translational research and autologous cell therapies, while multiparameter flow cytometry drives immunophenotyping in hematological diagnostics and minimal residual disease assessment. Imaging technologies encompass computed tomography, magnetic resonance imaging, positron emission tomography, and ultrasound, with each modality contributing unique value to diagnosis, staging, and treatment monitoring; PET and MRI are particularly pivotal where metabolic and functional readouts inform targeted therapy selection, whereas CT and ultrasound continue to offer broad accessibility and rapid imaging endpoints in acute care and outpatient pathways.

Immunohistochemistry subdivisions between chromogenic and fluorescent approaches reflect a trade-off between established workflows and higher-plex spatial resolution, with chromogenic methods maintaining ubiquity in routine pathology while fluorescent assays enable multiplexed biomarker panels and spatial profiling. In situ hybridization remains critical for detecting gene rearrangements and copy number changes within tissue architecture, complementing molecular diagnostics that span microarray, PCR, and sequencing technologies. Within molecular diagnostics, microarray applications persist where broad gene expression profiling is needed, PCR maintains a central role for targeted mutation detection and minimal residual disease assays due to its sensitivity and turnaround speed, and sequencing delivers comprehensive genomic insights that increasingly underpin precision oncology decisions.

Cancer-type segmentation highlights divergent diagnostic needs between hematological malignancies and solid tumors. Hematological cancers, including leukemia, lymphoma, and multiple myeloma, rely heavily on flow cytometry, molecular assays, and bone marrow-focused workflows for diagnosis, disease classification, and therapy monitoring. Solid tumors, comprising breast, colorectal, lung, and prostate cancers among others, demand integrated pipelines that combine tissue-based immunohistochemistry, in situ hybridization, and sequencing to inform biomarker-driven treatment selection. Each cancer subtype presents unique specimen handling, assay sensitivity, and biomarker validation requirements that shape commercial strategies.

End-user segmentation across ambulatory care, diagnostic laboratories, hospitals, and research institutes influences adoption velocity and procurement complexity. Ambulatory settings prioritize point-of-care efficiency and rapid reporting, whereas diagnostic laboratories emphasize throughput, accreditation compliance, and cost per test. Hospitals must balance in-house capacity with referral networks, often favoring integrated vendor solutions with service and training bundles. Research institutes, including academic centers and private research centers, drive early adoption of novel platforms and provide critical evidence-generation partnerships, acting as both customers and collaborators in assay validation and clinical utility studies. Collectively, these segmentation dynamics underscore the need for differentiated value propositions tailored to clinical workflows, reimbursement environments, and the operational constraints of each end-user cohort.

How divergent reimbursement regimes, regulatory frameworks, and healthcare infrastructures across global regions shape adoption priorities and commercial strategies

Regional dynamics exert a strong influence on technology adoption, reimbursement pathways, and partnership models across the Americas, Europe, Middle East & Africa, and Asia-Pacific, each exhibiting distinct healthcare structures and innovation ecosystems. In the Americas, mature private and public payers coexist with leading academic centers and a robust commercial diagnostics sector; this environment supports rapid uptake of high-value molecular tests and advanced imaging but also demands strong evidentiary programs to secure reimbursement and formulary positioning. Furthermore, procurement practices in the Americas often favor integrated service arrangements and long-term service contracts, which can advantage vendors that offer comprehensive post-sales support and consumable supply networks.

In Europe, Middle East & Africa, reimbursement systems are more heterogeneous and often more prescriptive about test reimbursement criteria, which can slow adoption of novel diagnostics without strong health economic data. Regulatory harmonization efforts in Europe promote cross-border collaboration, while pockets of innovation in the Middle East and Africa are driven by government-led investments in tertiary care and diagnostic infrastructure. Vendors operating in this region must navigate diverse national reimbursement frameworks and prioritize local evidence generation and partnerships with accredited laboratories to scale adoption.

Asia-Pacific presents a rapidly expanding opportunity space characterized by varied maturity across markets, from advanced economies with high adoption of sequencing and digital pathology to emerging markets where point-of-care diagnostics and cost-effective imaging are paramount. Government-led initiatives to strengthen cancer screening programs and investments in domestic manufacturing capacity are shaping procurement preferences and local partnerships. Across Asia-Pacific, considerations such as regulatory pathway clarity, localization of technical support, and pricing sensitivity play decisive roles in go-to-market strategies.

Taken together, these regional distinctions call for differentiated commercial playbooks that balance global platform consistency with localized evidence generation, regulatory navigation, and tailored service models. Strategic alliances with regional distributors, targeted clinical partnerships, and adaptive pricing strategies will be instrumental in translating product capabilities into sustainable clinical and commercial uptake across diverse health systems.

Competitive dynamics shaped by platform scale, assay specialization, service economics, and strategic alliances that together determine commercial resilience and growth trajectories

Competitive dynamics in diagnostic oncology are defined by a mix of large integrated platform providers, specialized assay developers, and agile newcomers focused on niche clinical applications. Established instrument manufacturers continue to leverage scale, broad service footprints, and integrated consumable ecosystems to defend installed bases, while specialist companies differentiate through assay innovation, software-enabled analytics, and strategic partnerships with clinical centers. Across the competitive landscape, differentiation increasingly hinges on the ability to demonstrate clinical utility, streamline laboratory workflows through automation, and provide durable service and reagent supply arrangements.

Partnerships and acquisitions remain central to capability expansion. Larger diagnostic firms frequently pursue bolt-on acquisitions to augment sequencing capacity, add multiplexed immunoassay capabilities, or incorporate digital pathology and AI-enabled interpretation tools. Meanwhile, smaller developers often seek co-development agreements with academic medical centers and contract research organizations to accelerate clinical validation and create reference datasets that support regulatory submissions and payer discussions. Strategic collaborations between instrument manufacturers and specialty reagent providers are also common, aligning product roadmaps to create bundled propositions that simplify procurement and ensure reagent availability.

Service economics and consumables revenue streams play a critical role in commercial viability. Vendors that combine robust field service networks with predictable consumable revenue models benefit from higher lifetime customer value and greater resilience against procurement cycle volatility. Software and informatics offerings further differentiate vendors by enabling data integration across modalities, facilitating longitudinal patient tracking, and supporting real-world evidence generation. Companies that invest in cloud-enabled platforms and interoperable data standards can unlock higher value by offering analytics-as-a-service and by simplifying multi-modal diagnostic workflows for clinical laboratories and health systems.

Overall, the competitive environment rewards organizations that combine scientific excellence with operational execution: those that can rapidly validate clinical utility, ensure uninterrupted reagent and service availability, and deliver interoperable diagnostic ecosystems will be best positioned to capture growing demand in precision oncology.

Prioritized strategic actions for diagnostics leaders to strengthen supply resilience, evidence-generation, and integrated clinical deployment for sustainable growth

Industry leaders should pursue a set of pragmatic, prioritized actions to convert emerging trends into durable competitive advantage. First, invest in supply chain transparency and diversification to reduce exposure to tariff- or trade-driven disruptions; this includes assessing alternative suppliers, evaluating regional manufacturing or co-manufacturing opportunities, and implementing inventory strategies that balance working capital with continuity of supply. Second, develop evidence-generation roadmaps that demonstrate clinical utility and health-economic value across key indications; early investment in prospective studies and real-world evidence will accelerate payer engagement and facilitate reimbursement discussions, particularly for high-cost molecular tests and companion diagnostics.

Third, prioritize product interoperability and integration with clinical workflows by adopting open standards and building partnerships with electronic health record and laboratory information system vendors. Simplifying integration reduces adoption friction in hospitals and reference laboratories and increases the stickiness of diagnostic solutions. Fourth, tailor commercial models to regional realities; deploy flexible pricing and contracting approaches that account for differing reimbursement environments and procurement cycles, and invest in regional service capabilities where uptime and consumable access are central to customer satisfaction.

Fifth, cultivate strategic partnerships with academic centers, clinical networks, and research institutes to accelerate validation, generate robust datasets, and co-create clinical pathways that embed diagnostics into standard care. These collaborations can also serve as early-warning systems for emerging clinical needs and regulatory trends. Finally, embed agility into R&D and commercialization processes by adopting modular development approaches, shortening iteration cycles, and aligning product development with evolving payer evidence requirements. Together, these actions balance risk mitigation with growth orientation and position organizations to scale responsibly in a dynamic oncology diagnostics market.

A robust mixed-methods research framework combining stakeholder interviews, literature synthesis, quantitative mapping, and expert validation to ensure evidence-based findings

The research underpinning this executive synthesis employed a mixed-methods approach designed to triangulate insights from multiple, complementary sources and to validate findings through expert consultation. Primary research included structured interviews with clinical leaders, laboratory directors, and procurement executives across hospitals, diagnostic laboratories, and research institutes, supplemented by interviews with senior executives from diagnostic manufacturing organizations and technology vendors. These engagements provided qualitative context on adoption drivers, procurement constraints, and the evidence needs that influence reimbursement decisions.

Secondary research encompassed a systematic review of peer-reviewed clinical literature, regulatory guidance documents, technical white papers, and public disclosures relating to diagnostic technologies, assay performance characteristics, and clinical utility studies. Where available, real-world datasets and registry analyses were assessed to contextualize diagnostic pathways and to identify patterns in assay utilization and clinical decision-making. Insights from these sources were synthesized to identify convergent themes and to cross-validate claims made in primary interviews.

Quantitative analyses included mapping of product portfolios against segmentation matrices, assessment of supply chain concentration for critical components, and scenario analysis to evaluate potential impacts of policy shifts such as tariff changes. Findings were stress-tested via expert panels comprising pathologists, molecular diagnostic scientists, radiologists, and health economics specialists to ensure clinical plausibility and to refine recommendations. Throughout the process, methodological rigor was maintained through transparent documentation of interview protocols, source attribution, and limitations, enabling readers to assess the strength of evidence behind key conclusions.

Synthesis of strategic imperatives showing that clinical utility, supply chain resilience, and integrated solutions determine long-term success in oncology diagnostics

The cumulative analysis points to a diagnostic oncology ecosystem at a strategic inflection point where technological potential, payer expectations, and supply chain realities intersect. Opportunities abound for organizations that can translate technological differentiation into demonstrable clinical value while ensuring operational resilience in the face of trade and procurement volatility. The trend toward multimodal diagnostics and integrated reporting will increasingly favor vendors that provide interoperable solutions and active collaboration with clinical stakeholders to embed diagnostics into care pathways.

At the same time, the landscape will reward disciplined evidence generation and adaptive commercial models. Tests and platforms that lack robust demonstration of clinical utility and cost-effectiveness will face adoption headwinds, particularly in markets with conservative reimbursement frameworks. Additionally, the capacity to manage supply chain complexity, whether through localization, diversified sourcing, or strategic partnerships, will be a deciding factor in sustaining market access and customer trust.

In sum, the organizations most likely to capture long-term value are those that align scientific innovation with pragmatic deployment strategies: they will invest in high-quality evidence, build resilient supply and service networks, and design interoperable, clinician-friendly solutions that reduce friction in real-world practice. These priorities will serve as the foundation for scalable growth in the evolving oncology diagnostics marketplace.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Cancer Diagnostics Market, by Technology

  • 8.1. Flow Cytometry
    • 8.1.1. Cell Sorting
    • 8.1.2. Multiparameter Flow Cytometry
  • 8.2. Imaging
    • 8.2.1. Computed Tomography
    • 8.2.2. Magnetic Resonance Imaging
    • 8.2.3. Positron Emission Tomography
    • 8.2.4. Ultrasound
  • 8.3. Immunohistochemistry
    • 8.3.1. Chromogenic
    • 8.3.2. Fluorescent
  • 8.4. In Situ Hybridization
  • 8.5. Molecular Diagnostics
    • 8.5.1. Microarray
    • 8.5.2. Pcr
    • 8.5.3. Sequencing

9. Cancer Diagnostics Market, by Cancer Type

  • 9.1. Hematological Cancers
    • 9.1.1. Leukemia
    • 9.1.2. Lymphoma
    • 9.1.3. Multiple Myeloma
  • 9.2. Solid Tumors
    • 9.2.1. Breast Cancer
    • 9.2.2. Colorectal Cancer
    • 9.2.3. Lung Cancer
    • 9.2.4. Prostate Cancer

10. Cancer Diagnostics Market, by End User

  • 10.1. Ambulatory Care
  • 10.2. Diagnostic Laboratories
  • 10.3. Hospitals
  • 10.4. Research Institutes
    • 10.4.1. Academic Institutes
    • 10.4.2. Private Research Centers

11. Cancer Diagnostics Market, by Region

  • 11.1. Americas
    • 11.1.1. North America
    • 11.1.2. Latin America
  • 11.2. Europe, Middle East & Africa
    • 11.2.1. Europe
    • 11.2.2. Middle East
    • 11.2.3. Africa
  • 11.3. Asia-Pacific

12. Cancer Diagnostics Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. Cancer Diagnostics Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. United States Cancer Diagnostics Market

15. China Cancer Diagnostics Market

16. Competitive Landscape

  • 16.1. Market Concentration Analysis, 2025
    • 16.1.1. Concentration Ratio (CR)
    • 16.1.2. Herfindahl Hirschman Index (HHI)
  • 16.2. Recent Developments & Impact Analysis, 2025
  • 16.3. Product Portfolio Analysis, 2025
  • 16.4. Benchmarking Analysis, 2025
  • 16.5. Abbott Laboratories
  • 16.6. Agilent Technologies, Inc.
  • 16.7. Becton, Dickinson and Company
  • 16.8. Bio-Rad Laboratories, Inc.
  • 16.9. bioMerieux SA
  • 16.10. Canon Medical Systems Corporation
  • 16.11. Danaher Corporation
  • 16.12. Danaher Corporation
  • 16.13. DiaSorin S.p.A.
  • 16.14. F. Hoffmann-La Roche Ltd
  • 16.15. Fujifilm Corporation
  • 16.16. GE HealthCare Technologies Inc.
  • 16.17. Hologic, Inc.
  • 16.18. Illumina, Inc.
  • 16.19. Myriad Genetics, Inc.
  • 16.20. NeoGenomics Laboratories, Inc.
  • 16.21. PerkinElmer, Inc.
  • 16.22. QIAGEN N.V.
  • 16.23. Quest Diagnostics Incorporated
  • 16.24. Siemens Healthineers AG
  • 16.25. Sysmex Corporation
  • 16.26. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CANCER DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CANCER DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 11. CHINA CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY CELL SORTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY CELL SORTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY CELL SORTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY MULTIPARAMETER FLOW CYTOMETRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY MULTIPARAMETER FLOW CYTOMETRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY MULTIPARAMETER FLOW CYTOMETRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY ULTRASOUND, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY ULTRASOUND, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY ULTRASOUND, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY CHROMOGENIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY CHROMOGENIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY CHROMOGENIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY FLUORESCENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY FLUORESCENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY FLUORESCENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY IN SITU HYBRIDIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY IN SITU HYBRIDIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY IN SITU HYBRIDIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY MICROARRAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY MICROARRAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY MICROARRAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY PCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY PCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY PCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY HEMATOLOGICAL CANCERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY HEMATOLOGICAL CANCERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY HEMATOLOGICAL CANCERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY LEUKEMIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY LEUKEMIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY LYMPHOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY LYMPHOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY MULTIPLE MYELOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY MULTIPLE MYELOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY MULTIPLE MYELOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY SOLID TUMORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY SOLID TUMORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY COLORECTAL CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY LUNG CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY PROSTATE CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY AMBULATORY CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY AMBULATORY CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY AMBULATORY CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY ACADEMIC INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY ACADEMIC INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY ACADEMIC INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY PRIVATE RESEARCH CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY PRIVATE RESEARCH CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY PRIVATE RESEARCH CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS CANCER DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 108. AMERICAS CANCER DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 109. AMERICAS CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 110. AMERICAS CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 111. AMERICAS CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 112. AMERICAS CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. AMERICAS CANCER DIAGNOSTICS MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
  • TABLE 114. AMERICAS CANCER DIAGNOSTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 115. AMERICAS CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 116. AMERICAS CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 122. NORTH AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 126. NORTH AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 132. LATIN AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 133. LATIN AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 134. LATIN AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. LATIN AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
  • TABLE 136. LATIN AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 138. LATIN AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE, MIDDLE EAST & AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE, MIDDLE EAST & AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE, MIDDLE EAST & AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE, MIDDLE EAST & AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE, MIDDLE EAST & AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE, MIDDLE EAST & AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE, MIDDLE EAST & AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE, MIDDLE EAST & AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE, MIDDLE EAST & AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE, MIDDLE EAST & AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE CANCER DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE CANCER DIAGNOSTICS MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE CANCER DIAGNOSTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. MIDDLE EAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 163. MIDDLE EAST CANCER DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 164. MIDDLE EAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 165. MIDDLE EAST CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 166. MIDDLE EAST CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 167. MIDDLE EAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. MIDDLE EAST CANCER DIAGNOSTICS MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
  • TABLE 169. MIDDLE EAST CANCER DIAGNOSTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 170. MIDDLE EAST CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 171. MIDDLE EAST CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 172. AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 173. AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 174. AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 175. AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 176. AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 177. AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 178. AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 179. AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
  • TABLE 180. AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 181. AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 182. AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 183. ASIA-PACIFIC CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. ASIA-PACIFIC CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 185. ASIA-PACIFIC CANCER DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 186. ASIA-PACIFIC CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 187. ASIA-PACIFIC CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 188. ASIA-PACIFIC CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 189. ASIA-PACIFIC CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 190. ASIA-PACIFIC CANCER DIAGNOSTICS MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
  • TABLE 191. ASIA-PACIFIC CANCER DIAGNOSTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 192. ASIA-PACIFIC CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 193. ASIA-PACIFIC CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 194. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 195. ASEAN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 196. ASEAN CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 197. ASEAN CANCER DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 198. ASEAN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 199. ASEAN CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 200. ASEAN CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 201. ASEAN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 202. ASEAN CANCER DIAGNOSTICS MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
  • TABLE 203. ASEAN CANCER DIAGNOSTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 204. ASEAN CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 205. ASEAN CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 206. GCC CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 207. GCC CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 208. GCC CANCER DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 209. GCC CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 210. GCC CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 211. GCC CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 212. GCC CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. GCC CANCER DIAGNOSTICS MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
  • TABLE 214. GCC CANCER DIAGNOSTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 215. GCC CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 216. GCC CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPEAN UNION CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPEAN UNION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPEAN UNION CANCER DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPEAN UNION CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPEAN UNION CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPEAN UNION CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPEAN UNION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPEAN UNION CANCER DIAGNOSTICS MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPEAN UNION CANCER DIAGNOSTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPEAN UNION CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPEAN UNION CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 228. BRICS CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 229. BRICS CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 230. BRICS CANCER DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 231. BRICS CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 232. BRICS CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 233. BRICS CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 234. BRICS CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 235. BRICS CANCER DIAGNOSTICS MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
  • TABLE 236. BRICS CANCER DIAGNOSTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 237. BRICS CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 238. BRICS CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 239. G7 CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 240. G7 CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 241. G7 CANCER DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 242. G7 CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 243. G7 CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 244. G7 CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 245. G7 CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 246. G7 CANCER DIAGNOSTICS MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
  • TABLE 247. G7 CANCER DIAGNOSTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 248. G7 CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 249. G7 CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 250. NATO CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 251. NATO CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 252. NATO CANCER DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 253. NATO CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 254. NATO CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 255. NATO CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 256. NATO CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 257. NATO CANCER DIAGNOSTICS MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
  • TABLE 258. NATO CANCER DIAGNOSTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 259. NATO CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 260. NATO CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 261. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 262. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 263. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 264. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 265. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 266. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 267. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 268. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 269. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
  • TABLE 270. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 271. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 272. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 273. CHINA CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 274. CHINA CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 275. CHINA CANCER DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 276. CHINA CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 277. CHINA CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 278. CHINA CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 279. CHINA CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 280. CHINA CANCER DIAGNOSTICS MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
  • TABLE 281. CHINA CANCER DIAGNOSTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 282. CHINA CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 283. CHINA CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)